Results 131 to 140 of about 1,312,052 (154)

Author Correction: Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis. [PDF]

Sci Rep
Murata K, Uozumi R, Fujii T, Onishi A, Murakami K, Onizawa H, Tanaka M, Morinobu A, Matsuda S.   +8 more
europepmc   +1 more source

Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study. [PDF]

Rheumatology (Oxford)
van der Togt CJT, den Broeder N, Boonstra MS, van der Maas A, den Broeder AA, van Herwaarden N.   +5 more
europepmc   +1 more source

Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries. [PDF]

Arthritis Res Ther
Ciurea A, Kissling S, Götschi A, Ørnbjerg LM, Rasmussen SH, Tamási B, Möller B, Nissen MJ, Glintborg B, Loft AG, Scherer A, Bräm R, Pavelka K, Závada J, Dias JM, Valente P, Gudbjornsson B, Palsson O, Rantalaiho V, Peltomaa R, Codreanu C, Mogosan C, Iannone F, Sebastiani M, Jones GT, Macfarlane GJ, Castrejon I, Rotar Z, Michelsen B, Wallman JK, van der Horst-Bruinsma I, Distler O, Østergaard M, Hetland ML, Micheroli R, Ospelt C.   +35 more
europepmc   +1 more source

Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles. [PDF]

Front Pharmacol
Silvagni E, Bortoluzzi A, Occhino G, Bellelli G, Garaffoni C, Delvino P, Leoni O, Valsecchi MG, Scirè CA, Rebora P.   +9 more
europepmc   +1 more source

Work loss in patients with rheumatoid arthritis treated with abatacept, rituximab, tocilizumab or TNF inhibitors: a nationwide direct drug-to-drug comparison. [PDF]

RMD Open
Bruze GM, Frisell T, Turesson C, Forsblad-d'Elia H, Soderling J, Askling J, Neovius M, ARTIS Study Group.   +7 more
europepmc   +1 more source

Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis. [PDF]

Sci Rep
Murata K, Uozumi R, Fujii T, Onishi A, Murakami K, Onizawa H, Tanaka M, Morinobu A, Matsuda S.   +8 more
europepmc   +1 more source

Maternal and perinatal outcomes in pregnant women with rheumatic diseases treated with biosimilar TNF inhibitors. [PDF]

Rheumatol Adv Pract
Chícharo AT, Lopes AR, Barreira S, Pinto L, Cruz-Machado AR, Capela S.   +5 more
europepmc   +1 more source

Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching. [PDF]

Rheumatology (Oxford)
Linde L, Ørnbjerg LM, Heegaard Brahe C, Wallman JK, Di Giuseppe D, Závada J, Castrejon I, Díaz-Gonzalez F, Rotar Z, Tomšič M, Glintborg B, Gudbjornsson B, Geirsson AJ, Michelsen B, Kristianslund EK, Santos MJ, Barcelos A, Nordström D, Eklund KK, Ciurea A, Nissen M, Akar S, Hejl Hyldstrup L, Krogh NS, Hetland ML, Østergaard M.   +25 more
europepmc   +1 more source

Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis. [PDF]

Sci Rep
Cha S, Bang SY, Joo YB, Cho SK, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Lee HS, Bae SC.   +10 more
europepmc   +1 more source

Correlation between Trabecular Bone Score and Homocysteine Level in Rheumatoid Arthritis Patients on Anti-TNF Inhibitors. [PDF]

Life (Basel)
Ioniță-Radu F, Nicolau IN, Petrache OG, Groșeanu ML, Bojincă VC, Negru MM, Bucurică S, Anghel D.   +7 more
europepmc   +1 more source